One- versus two-surgeon active stone retrieval procedures for flexible ureteroscopy: An off-site simulator comparative study.

OBJECTIVES: To evaluate the efficacy of the one-surgeon basketing technique compared to the conventional two-surgeon method for flexible ureteroscopy. METHODS: Seven urologists (three trained and four less-trained surgeons) extracted three renal stones using each technique with an off-site simulator. We analyzed the task completion time, the number of times the basket forceps were opened and closed, and unexpected events during stone-catching, for both techniques. RESULTS: There was no significant difference in the total task completion time between the one-surgeon (102.0 [interquartile range 63.5-164.0] s) and two-surgeon (99.5 [interquartile range 75.0-145.3] s) techniques. However, the time it took the trained surgeons to extract all stones was significantly shorter with the one-surgeon than with the two-surgeon technique (19.0 [interquartile range 18.0-20.0] s vs 34.0 [interquartile range 25.0-40.0] s; P = 0.049). Among the less-trained surgeons, the opposite effect was observed, but this difference was not statistically significant (96.5 [interquartile range 61.0-134.5] s vs 64.0 [interquartile range 51.5-77.0] s; P = 0.489). The number of times the forceps were opened and closed during stone-catching was significantly lower with the one-surgeon technique than with the two-surgeon technique (5.0 [interquartile range 4.0-5.0] times vs 9.0 [interquartile range 6.0-14.5] times; P = 0.018). CONCLUSIONS: The one-surgeon technique can offer comparable efficacy to the two-surgeon technique. If surgeons are sufficiently trained, a one-surgeon basketing technique for performing flexible ureteroscopy might become a new technical modality for extracting renal stones.

Safety and Effectiveness of Holmium Laser Enucleation of the Prostate Using a Low-power Laser.

OBJECTIVE: To assess the safety and effectiveness of holmium laser enucleation of the prostate (HoLEP) using a low-power 30-W holmium laser with an en bloc enucleation technique. MATERIALS AND METHODS: We retrospectively analyzed 74 patients with a diagnosis of benign prostatic hyperplasia treated with HoLEP using a 30-W laser set at 1.5 J with a frequency of 20 Hz, as a low-power setting. The enucleation process was performed using the en bloc technique. Forty-four patients were operated on by an experienced surgeon, whereas 30 patients were operated on by 2 less experienced surgeons. We evaluated the surgical parameters and practicality of the low-power laser. RESULTS: All patients underwent successful HoLEP with the low-power setting; it was not necessary to increase the output of the laser in any case. Mean preoperative estimated prostate volume was 94.5 mL (range 22-489 mL). Mean total operating time and enucleation time were 91.9 minutes (range 30-232 minutes) and 45.4 minutes (range 13-101 minutes), respectively. No patient required blood transfusion postoperatively. Other intraoperative complications, including capsular perforation and ureteral orifice injury, did not occur. In 55 patients without preoperative stress urinary incontinence (SUI), postoperative SUI was observed in 7 patients (12.7%) at 1 month postoperatively, and in 3 patients (5.5%) at 3 months postoperatively. CONCLUSION: HoLEP using a low-power 30-W holmium laser can be performed safely and without any technical problems; this low-power setting is thought to be sufficient for performing HoLEP. As the introduction costs can be reduced by using a low-power laser, HoLEP could become widespread.

En-Bloc Technique With Anteroposterior Dissection Holmium Laser Enucleation of the Prostate Allows a Short Operative Time and Acceptable Outcomes.

OBJECTIVE: To simplify anteroposterior dissection holmium laser enucleation of the prostate by combining it with a novel en-bloc enucleation technique that omits median lobe enucleation and removes the adenoma en-bloc in benign prostatic hyperplasia patients. METHODS: Between September 2013 and May 2014, 65 patients with benign prostatic hyperplasia underwent holmium laser enucleation of the prostate with the en-bloc technique we developed at our institution. Twenty-six patients who underwent surgery performed by the same experienced surgeon were included in our study. We evaluated the surgical parameters, including total operative time, enucleation time, morcellation time, and hemoglobin loss. Peak flow rate and postvoid residual urine volume were assessed 3 months postoperatively, and urinary incontinence was assessed 1 day after catheter removal and at 1 and 3 months postoperatively in all patients. RESULTS: Mean total operating time and mean enucleation time were 56.4 and 26.5 minutes, respectively. Peak flow rate and postvoid residual urine volume significantly improved. The incidence of postoperative incontinence at 3 months was 3%. CONCLUSION: Our en-bloc enucleation method required a short operating time and may address concerns regarding the complexity of the enucleation procedure. We believe the incidence of postoperative incontinence can be further reduced with additional refinements of this procedure.

[Organ-sparing surgery for contralateral testicular tumor following orchiectomy : a case report].

A 30-year-old man underwent a left high orchiectomy because of stage I testicular tumor in December, 2006. A palpable nodule was noticed in the contralateral testicle in March, 2008. No tumor marker was elevated. Imaging studies including ultrasonography and magnetic resonance imaging showed a 13 mm tumor consisting of both a solid portion and a hemorrhagic cyst. A malignant tumor could not be ruled out completely based on examinations and his medical history. Tumor resection with partial orchiectomy was planned after informed consent. Preoperative serum concentration of free testosterone was 8.4 pg/ml, and motile sperm were found in the semen analysis. The tumor was resected while the spermatic cord was clamped transiently. The pathological diagnosis of frozen sections confirmed no malignancy, and the final pathological result was mature teratoma, no evidence of malignancy. No androgen substitution has been required. Furthermore, a few normal motile sperm were detected in the ejaculated semen after the surgery. Organ-sparing surgery for the contralateral testicular tumor following orchiectomy, can be considered to avoid infertility and hormonal substitutions.

Anteroposterior dissection HoLEP: a modification to prevent transient stress urinary incontinence.

OBJECTIVES: The prevalence of transient stress urinary incontinence (SUI) after HoLEP has been reported to be as high as 44%. Anteroposterior dissection HoLEP was newly developed to protect the urethral sphincter and therefore lower the incidence rate of SUI. This study was conducted to determine the SUI incidence rate after anteroposterior dissection HoLEP. METHODS: Sixty-eight consecutive patients with benign prostatic hyperplasia underwent HoLEP from January to December 2008. The first 31 cases (Surgery 1) underwent HoLEP according to Gilling's method. The next 37 cases (Surgery 2) underwent anteroposterior dissection HoLEP, where adenoma was dissected antegradely. This antegrade movement of the cystoscope allows the apical gland to be removed from the sphincter without causing damage. Surgical quality indexes (hemoglobin change, operating time, resected prostate volume) between the 2 groups were compared. All patients were assessed at 2 weeks postoperatively for clinical SUI, international prostate symptom score (IPSS), quality of life (QoL), and peak flow rates (Q(max)). RESULTS: Patient characteristics and surgical quality indexes did not differ between the 2 groups. Clinical SUI was found in 25.2% of cases in the Surgery 1 group, but only 2.7% in the Surgery 2 group. IPSS, QoL and Q(max.) were significantly improved postoperatively in both groups. At 2 weeks, the QoL of the Surgery 2 group was significantly improved compared with that observed for Surgery 1 (1.5 ± 1.1 vs 2.4 ± 1.0, P = .02). The Q(max.) of Surgery 2 was significantly higher compared with Surgery 1 (19.8 ± 8.4 vs 13.0 ± 4.7 ml/s, P = .02). CONCLUSIONS: These results indicate that our anteroposterior dissection HoLEP is a promising procedure to avoid postoperative SUI and also to substantially improve QoL.

Activation of natural killer T cells by alpha-galactosylceramide mediates clearance of bacteria in murine urinary tract infection.

PURPOSE: alpha-Galactosylceramide (alpha-GalCer), which is a specific ligand for CD1d restricted variable-alpha14chain natural killer T cells, has an important role in host defense against a range of microbial infections. We examined whether alpha-GalCer mediates bacterial clearance in a murine urinary tract infection (UTI) model. MATERIALS AND METHODS: The murine UTI model was established by intravesical inoculation of Escherichia coli, Pseudomonas aeruginosa or methicillin resistant Staphylococcus aureus, followed by clamping the distal end of the urethra of C57BL/6 female mice for 4 hours. The antibacterial effect of alpha-GalCer was assessed by comparing the number of cfu/gm kidney tissue 4 days after bacterial inoculation. The prophylactic effect of alpha-GalCer was examined by administrating 3 doses of intraperitoneal alpha-GalCer on alternate days 24 hours before E. coli inoculation. The therapeutic effect of alpha-GalCer was tested by the administration of 2 doses of intraperitoneal alpha-GalCer after bacterial inoculation. To assess cytokine induction by alpha-GalCer serum levels of interleukin-12, interferon-gamma and tumor necrosis factor-alpha were measured by cytometric bead array assay. RESULTS: When administered before bacterial inoculation, alpha-GalCer showed a strong prophylactic antibacterial effect. alpha-GalCer also showed a marked antibacterial effect on preestablished mice UTI caused by E. coli, P. aeruginosa and methicillin resistant S. aureus. alpha-GalCer induced a significantly higher level of interleukin-12, interferon-gamma and tumor necrosis factor-alpha compared with control glycolipids. CONCLUSIONS: These findings suggest a significant role for alpha-GalCer in regulating antibacterial functions by activating natural killer T cells in the murine UTI model.

[Two cases of urothelial cancer responsive to high-dose-intensity methotrexate vinblastine doxorubicin and cisplatin (M-VAC) therapy].

We report two cases of metastatic urothelial cancer treated with high-dose-intensity (HD) methotrexate vinblastine, doxorubicin and cisplatin (MVAC). After HD-MVAC, the size of primary and lymph node tumors decreased by 57-67% as compared with the standard M-VAC therapy. By shortening the dose interval, HD-MVAC may increase the anti-tumor effect without increasing side effects.

Functional correlation of trophinin expression with the malignancy of testicular germ cell tumor.

Trophinin is a membrane protein that is potentially involved in human embryo implantation by mediating homophillic cell adhesion between trophoblastic cells and endometrial cells. Trophinin expression by maternal cells may be induced by the embryo that secretes human chorionic gonadotropin (hCG). Because the process of tumor metastasis resembles that of trophoblast invasion and proliferation during embryo implantation, we hypothesized that testicular cancers that synthesize hCG express trophinin thus becoming aggressive trophoblast-like cells. We screened paraffin-embedded orchiectomy specimens of 158 patients with testicular germ cell tumor by immunohistochemistry using antitrophinin antibody. This screening identified trophinin-positive specimens with the frequencies 39 of 91 (43%) in stage I, 14 of 24 (58%) in stage II, and 41 of 43 (95%) in stage III (P < 0.001). Thus, trophinin expression positively correlates with clinical stage. Remarkably, trophinin was found in all of the cases (33 of 33) with lung metastasis. The levels of serum hCG-beta were significantly higher in the patients with trophinin-positive tumors than those with trophinin-negative tumors (P = 0.004). To determine whether trophinin promotes aggressiveness of the cell, trophinin-negative human seminona cell line JKT-1 was stably transfected with a mammalian expression vector containing trophinin cDNA. In vitro assays revealed that trophinin-expressing JKT-1-Tro cells are more invasive than JKT-1-mock cells, whereas there are no differences between JKT-1-Tro and JKT-1-mock in their proliferation activity. Upon orthotopic inoculation to athymic nude mice, JKT-1-Tro cells exhibited i.p. metastases in all of the mice (n = 5), whereas JKT-1-mock produced no metastases (n = 5). These results suggest strongly that trophinin enhances invasiveness of the cells and promotes metastasis of testicular germ cell tumor.